ONP-002 Advances Toward Phase IIa Concussion Trial with Strengthened Financial Foundation and Industry MomentumSARASOTA, Fla.

Oragenics’ lead drug candidate, ONP-002, is a neuroprotective, anti-inflammatory compound delivered intranasally for the treatment of mild traumatic brain injury (mTBI) or concussion.

Despite the high incidence of concussions, no FDA-approved drug therapies currently exist, leaving a significant unmet medical need. “The submission of our Investigator’s Brochure application ...

Oragenics (OGEN), provided shareholders with an update on its strategic and financial progress for the first quarter of 2025. The Company has ...

ONP-002 is an intranasal therapeutic being developed for concussion and is designed to ... clinical trial and submitted the Investigator’s Brochure to regulatory authorities in Australia.

ONP-002 Advances Toward Phase IIa Concussion Trial with Strengthened Financial Foundation ... production for the Phase IIa clinical trial and submitted the Investigator's Brochure to regulatory ...

aiming to transform concussion treatment by enabling faster, more targeted care. Clinical Trial Advancements: Submitted the Investigator's Brochure (IB) for the Phase IIa clinical trial in ...

March 06, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, today announced ...